Literature DB >> 22572909

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations.

Filippo Brandimarte1, Muthiah Vaduganathan, Gian Francesco Mureddu, Giuseppe Cacciatore, Hani N Sabbah, Gregg C Fonarow, Steven R Goldsmith, Javed Butler, Francesco Fedele, Mihai Gheorghiade.   

Abstract

Numerous studies over the last decade have demonstrated that renal dysfunction and worsening renal function (WRF) are common in patients hospitalized for heart failure (HHF) and appear to be associated with poor in-hospital and post-discharge outcomes. Unfortunately, its etiology has not been completely understood, and its prediction during hospitalization remains challenging. The evaluation of renal impairment during hospitalization should take into consideration the underlying renal substrate (e.g., predisposing clinical comorbidities such as diabetes and hypertension), initiating mechanisms (e.g., in-hospital therapies such as diuretics), and amplifying factors (neurohormonal and hemodynamic profile changes). Various patterns of WRF may have different prognostic implications and may require different therapeutic approaches. WRF may be initially classified by duration (transient vs. persistent) and by etiology (elevated venous pressures vs. arterial underfilling). Other critical contributing factors during hospitalization include progressive left ventricular dysfunction, neurohormonal activation, and medications. Transient WRF as a result of aggressive therapy targeting congestion may not be associated with poor outcomes. Persistent WRF seen in patients with severe hemodynamic derangements may be associated with poor post-discharge prognosis. Future investigations must clarify the pathophysiological correlates of various patterns of WRF. To date, there is an unmet clinical need to achieve adequate control over congestion while preserving renal function in HHF patients. Thus, the aim of this review is to provide an in-depth and critical interpretation of the available data on the prognostic importance of RD and WRF during hospitalization in an effort to improve HF management.

Entities:  

Mesh:

Year:  2013        PMID: 22572909     DOI: 10.1007/s10741-012-9317-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  51 in total

1.  Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure.

Authors:  Robb D Kociol; Melissa A Greiner; Bradley G Hammill; Hemant Phatak; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

3.  Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure.

Authors:  Harini Chittineni; Nobuyuki Miyawaki; Sailaja Gulipelli; Steven Fishbane
Journal:  Am J Nephrol       Date:  2007-01-24       Impact factor: 3.754

4.  Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.

Authors:  John E A Blair; Peter S Pang; Robert W Schrier; Marco Metra; Brian Traver; Thomas Cook; Umberto Campia; Andrew Ambrosy; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Marvin A Konstam; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2011-07-23       Impact factor: 29.983

5.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  The significance of serum urea and renal function in patients with heart failure.

Authors:  Israel Gotsman; Donna Zwas; David Planer; Dan Admon; Chaim Lotan; Andre Keren
Journal:  Medicine (Baltimore)       Date:  2010-07       Impact factor: 1.889

7.  Relation of worsened renal function during hospitalization for heart failure to long-term outcomes and rehospitalization.

Authors:  David E Lanfear; Edward L Peterson; Janis Campbell; Hemant Phatak; David Wu; Karen Wells; John A Spertus; L Keoki Williams
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

8.  [Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile].

Authors:  Lilian Grigorian Shamagian; Alfonso Varela Román; Milagros Pedreira Pérez; Inés Gómez Otero; Alejandro Virgós Lamela; José R González-Juanatey
Journal:  Rev Esp Cardiol       Date:  2006-02       Impact factor: 4.753

9.  Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Authors:  Liviu Klein; Barry M Massie; Jeffrey D Leimberger; Christopher M O'Connor; Ileana L Piña; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

10.  Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival.

Authors:  Tom D J Smilde; Hans L Hillege; Gerjan Navis; Frans Boomsma; Dick de Zeeuw; Dirk J van Veldhuisen
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  7 in total

1.  Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

Authors:  Stephen J Greene; G Michael Felker; Anna Giczewska; Andreas P Kalogeropoulos; Andrew P Ambrosy; Hrishikesh Chakraborty; Adam D DeVore; Marat Fudim; Steven E McNulty; Robert J Mentz; Muthiah Vaduganathan; Adrian F Hernandez; Javed Butler
Journal:  Can J Cardiol       Date:  2019-02-07       Impact factor: 5.223

Review 2.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

3.  Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.

Authors:  Horng H Chen; Omar F AbouEzzeddine; Kevin J Anstrom; Michael M Givertz; Bradley A Bart; G Michael Felker; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

Review 4.  Cardiorenal syndrome: pathophysiology and treatment.

Authors:  Dmitry Shchekochikhin; Robert W Schrier; JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 5.  Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.

Authors:  Kalkidan Bishu; Margaret M Redfield
Journal:  Curr Heart Fail Rep       Date:  2013-09

6.  In-hospital mortality is associated with high NT-proBNP level.

Authors:  Malik Benmachiche; Pedro Marques-Vidal; Gérard Waeber; Marie Méan
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

7.  The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis.

Authors:  C J Taylor; A K Roalfe; R Iles; F D R Hobbs
Journal:  BMJ Open       Date:  2014-04-19       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.